Compare Delta Air Lines, Inc. (DAL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs GeneDx Holdings Corp — how do they compare? Delta Air Lines, Inc. trades at $85.79 (market cap $56.23B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Delta Air Lines, Inc. is far larger — about 30.4× GeneDx Holdings Corp's market cap, and Delta Air Lines, Inc. pays a 0.91% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| DAL | WGS | |
|---|---|---|
Market Cap | $56.23B | $1.85B |
Sector | Industrials | Technology |
52-Week High | $93.66 | $167.51 |
52-Week Low | $51.15 | $34.51 |
Enterprise Value | $71.55B | $1.85B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $86.19, down 1.37% on the day, with a bullish technical outlook supported by strong earnings beats and positive analyst sentiment. The stock shows solid fundamentals with a P/E of 14.29 and net income margin of 5.78%, while recent news highlights premium demand resilience and AI-driven customer satisfaction improvements. Cash flow trends have strengthened, with net cash flow turning positive in 2025 at $1.08 billion.
The outlook remains favorable with an 81.82% analyst buy rating and a $108.27 consensus price target implying 26% upside. Key risks include fuel cost volatility and competitive pressures, but strong institutional support and consistent earnings performance underpin potential for continued growth amid stable travel demand.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
